Details for Patent: 9,447,106
Which drugs does patent 9,447,106 protect, and when does it expire?
Patent 9,447,106 protects BRUKINSA and is included in two NDAs.
This patent has thirty-seven patent family members in twenty-nine countries.
Summary for Patent: 9,447,106
| Title: | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
| Abstract: | The invention is substituted 4,5-dihydro- and 4,5,6,7-tetrahydro-pyrazolo[1,5-α]pyrimidine compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor, such as inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby. |
| Inventor(s): | Zhiwei Wang, Yunhang Guo |
| Assignee: | BeOne Medicines I GmbH |
| Application Number: | US14/723,417 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,447,106
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beone Medicines Usa | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | DISCN | Yes | No | 9,447,106 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Start Trial | ||
| Beone Medicines Usa | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | DISCN | Yes | No | 9,447,106 | ⤷ Start Trial | Y | Y | FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA | ⤷ Start Trial | ||
| Beone Medicines Usa | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | DISCN | Yes | No | 9,447,106 | ⤷ Start Trial | Y | Y | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN | ⤷ Start Trial | ||
| Beone Medicines Usa | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | DISCN | Yes | No | 9,447,106 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) | ⤷ Start Trial | ||
| Beone Medicines Usa | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | DISCN | Yes | No | 9,447,106 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,447,106
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2989106 | ⤷ Start Trial | 301161 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2989106 | ⤷ Start Trial | PA2022504 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2989106 | ⤷ Start Trial | LUC00250 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2989106 | ⤷ Start Trial | CA 2022 00008 | Denmark | ⤷ Start Trial |
| European Patent Office | 2989106 | ⤷ Start Trial | 122022000013 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
